Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253331 · ClinicalTrials.gov registry record · Phase 2
Lab Study of MQX-503 in Treatment of Raynaud's
A Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT00253331: Completed Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma, sponsored by MediQuest Therapeutics.
NCT00253331 is a Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma that has completed, run by MediQuest Therapeutics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00253331, a Phase 2 study of Raynaud Disease and Raynaud Disease Secondary to Scleroderma, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures. Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours. Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.
Conditions Studied
Interventions
- DRUG topical organogel with nitroglycerin
Study Locations (2)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Washington
- University of Washington Medical College - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00253331 record still lists
NCT00253331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Raynaud Disease appearing as the primary indexed condition, and to 1 intervention - of which topical organogel with nitroglycerin is the first listed.
NCT00253331 reports a single indexed study location in Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT00253331 about?
NCT00253331 is a clinical study titled "Lab Study of MQX-503 in Treatment of Raynaud's". The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phen...
What is the current status of trial NCT00253331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-11. Estimated completion is 2005-09.
What conditions does trial NCT00253331 study?
This clinical trial studies the following conditions: Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease.
What interventions are being tested in trial NCT00253331?
The interventions under investigation include: topical organogel with nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00253331?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00253331 being conducted?
This trial has 2 study locations across Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00253331's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia